Biomedical products company Cerus has announced that Aalborg University Hospital, Denmark, has signed a five-year project collaboration agreement for the company’s INTERCEPT Blood System for platelets.
Aalborg University Hospital is the first hospital in Denmark to adopt INTERCEPT. The hospital’s department of FBE Klinisk Immunologi transfuses approximately 2,200 platelet units each year to Region Nordjylland, which represents around 6% of Denmark’s platelet market.
One of the most rampant infectious risks in blood transfusion is bacterial contamination of platelets, which poses serious health risks to transfusion patients. Cerus believes the INTERCEPT Blood system will substantially reduce residual risk due to bacterial contamination, also offering significant operational advantages like reduced waste rates.
INTERCEPT has shown improved patient outcomes over 10 years of routine use, as supported by hemovigilance data in which INTERCEPT-treated platelet components prevented septic transfusion reactions. Also favorably impacted have been logistics and component availability, resulting in cost-effective blood center operations.
Aalborg University Hospital has a proactive approach to protecting patients against transfusion-transmitted infections, and Cerus looks forward to working with the hospital in these efforts to improve blood safety. In the future, Cerus hopes to extend implementation of INTERCEPT platelets to other Danish centers.
For more information, visit www.cerus.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
